Results that speak for themselves.

• Take a moment and review the results of my recommendations.  I am confident that you will find them impressive.
• Most, if not all, of RXI's premium members have realized some nice gains and sufficient to justify the $200 annual membership. 

 Regular Content NEW!

• Features periodically posted articles & updates, available for everyone.
• I encourage you to check this section frequently.
• When you earn a gain from the content provided in this section, please support my efforts by subscribing to the site.  This means, the recommendations posted in this section are intended to help you generate a nice return on your investment.

 Premium Content

• Features regularly posted articles, alerts & updates made available only to RXI’s members. 
• To become a member, you must subscribe to RXI.
• Why subscribe to RXI's Premium Content?  Check out the results from my recommendations.  Most, if not all, of RXI's premium members have earned gains and sufficient to justify the annual rate of $200.

 NEW! Subscription Plans

• RXI is now offering Monthly, Quarterly & Annual Subscription Plans.
• The $20 Monthly Subscription Plan will only be available for new subscibers through Labor Day, Monday, September 6, 2010.  You can (and should) take advantage of this offer by subscribing today.

 Member Forum 

• After reviewing our Member Roster, it should be evident that our members give us a significant advantage over other investors. 
• Please note, many of our members prefer to remain anonymous and have NOT established a public member profile.  This means, many of RXI’s members are NOT included on our Member Roster.

 Open Positions

• Open Positions are simply buy recommendations that remain open until I issue a sell recommendation.
• Featured on the Open Positions page: (1) price targets, (2) time horizons, i.e. 12 months, (3) best / better / good opportunity rankings and (4) dated citations. 
• Since I launched RXI in mid-March 2010, I have made a total of 65 buy recommendations.  Out of all 65 buys, I have issued 32 sell recommendations.  Sells are closed Closed Positions.  Currently, there are 33 Open Positions.

 Closed Positions

• Closed positionsSell recommendations featuring the same info and data as Open Positions along with dated citations.
• Results are determined by the differnece between the buy and sell recommendations. 
• So far, 78.12% (25/32) of the buy recommendations that I have issued have been closed with a profit.  
• As result, most, if not all, of our premium members have realized nice gains.  I know because they email me and tell me.
• Notably, most of the sell recommendations were issued in June and in the eye of the 2010 correction which began in early May 2010. 
• Why subscribe to RXI?  78% profitability is hard to beat especially during a time when many stocks are experiencing dramatic swings, up and down.

 Catalyst Stocks NEW!

• Two lists of stocks featuring both a (1) Preferred List and an (2) Other List of drug, device and diagnostic makers with pending regulatory and/or clinical events (potential catalysts) throughout 2010 and 2012.  To simplify research, both lists, Preferred and Other, have been sorted by number of outstanding events. 
• RXI's Top 14 Upcoming Regulatory Reviews: I selected 14 drugs, devices and diagnostics that I believe will most likely be approved throughout 2010 and 2011.

 =================================